NUDT2 loss defines quantitative limits for dinucleoside polyphosphate action on the cGAS-STING-TBK1 axis
NUDT2 is an emerging candidate for therapeutic intervention in cancer, and its inhibition or loss is known to elevate adenosine-containing dinucleoside polyphosphates (ApnNs), including diadenosine tetraphosphate (Ap4A). Ap4A is a stress- and immune-associated nucleotide metabolite proposed to act as a second messenger, raising the possibility that NUDT2 targeting may unintentionally affect important nucleotide-sensitive signaling pathways. One such pathway is cGAS-STING signaling, a central innate immune axis that detects cytosolic DNA, produces the nucleotide second messenger 2'3'-cGAMP, and drives type I interferon responses. Because cGAS-STING also contributes to antitumor immunity and is being pharmacologically targeted in cancer, we asked whether sustained Ap4A accumulation perturbs this pathway. We systematically evaluated Ap4A and related dinucleoside polyphosphates across the cGAS-STING-TBK1 axis using biophysical, enzymatic, structural, and cellular approaches. Contrary to a previous model, STING did not bind Ap4A, Ap3A, or Ap4G, despite robust binding of canonical cyclic dinucleotides. Although cGAS bound these nucleotides with micromolar affinities, DNA-activated cGAMP synthesis was inhibited only at high, supra-substrate ratios. Similarly, TBK1 inhibition required extreme Ap4A ratios beyond physiologically relevant levels. In a THP-1 cell model, NUDT2 knockout caused strong Ap4A accumulation, but the resulting intracellular dinucleoside polyphosphate levels remained below the ratios required to inhibit cGAS or TBK1 in vitro. This study thus distinguishes biochemical possibility from physiological relevance and argues that NUDT2-linked Ap4A accumulation is unlikely to directly compromise cGAS-STING pathway activity.